Anixa Biosciences Enters Letter of Intent with VERDI Solutions to Develop Artificial Intelligence-Guided Personalized and Off-the-Shelf Cancer Vaccines

Anixa Biosciences Receives Notice of Allowance from USPTO for Ovarian Cancer Vaccine

Anixa Biosciences CEO to Present at the 2025 CAGLA NeauxCancer Conference on March 28th